Anavex Life Sciences (AVXL) 0.2600 $AVXL
Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
GlobeNewswire - Mon Jul 21, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies.
ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
GlobeNewswire - Mon Jul 14, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC).
Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
GlobeNewswire - Mon Jun 30, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that a paper in the current issue of the peer-reviewed scientific journal, Neurochemical Research, reveals for the first time that sigma-1 receptors (S1R) functionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety, epilepsy and brain injury following ischemic stroke.
Acute Pain - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlbxfm/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Nektar Therapeutics - Santen Pharmaceutical Co., Ltd. - Pacira Pharmaceuticals, Inc. - AcelRx Pharmaceuticals, Inc. - Laboratorios Del Dr. Esteve S.A. - Pfizer Inc. - Sigma-Tau S.p.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Anavex Life Sciences Corp. - Nuvo Research Inc. - Zalicus Inc. - Yungjin Pharm Ind. Co., Ltd. - Array BioPharma Inc. - Orexo AB - Insys Therapeutics, Inc. - Grunenthal GmbH - AngioChem Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - Syntrix Biosystems, Inc. - Kineta, Inc. - QRxPharma Limited - Cara Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - Encore Therapeutics Inc. - Madeira Therapeutics For more information visit http://www.researchandmarkets.com/research/qlbxfm/acute_pain
Anavex wins new US patent for ANAVEX 3-71 for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance
M2 - Thu Jun 05, 3:25AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) disclosed on Wednesday the receipt of the US Patent Number 8,673,931 covering ANAVEX 3-71 (formerly AF710B) for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance.
Anavex Awarded New U.S. Patent
GlobeNewswire - Wed Jun 04, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931 (the "Patent" . The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance. ANAVEX obtained exclusive rights to worldwide patents and patent applications for ANAVEX 3-71 and related compounds in March 2014 from Life Science Research Israel, a subsidiary of the Israel Institute for Biological Research. The Patent has a term that expires no earlier than April 29, 2030.
Anavex Life Sciences elects Dr Abraham Fisher to SAB
M2 - Thu May 29, 3:21AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) revealed on Wednesday the addition of Abraham Fisher PhD, to its scientific advisory board (SAB).
Stroke - Pipeline Review, H1 2014: Includes 62 Company Profiles
M2 - Thu May 29, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4c67qc/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Include: - AGY Therapeutics, Inc. - APT Therapeutics, Inc. - Acorda Therapeutics, Inc. - Ampio Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - Angion Biomedica Corp. - ArmaGen Technologies, Inc. - Aronora, LLC - AstraZeneca PLC - CHA Bio & Diostech Co., Ltd. - CardioVascular BioTherapeutics, Inc. - CoDa Therapeutics, Inc. - Covigilance sro - D-Pharm Ltd. - Diakron Pharmaceuticals, Inc. - Dongwha Pharm Co., Ltd. - Encore Therapeutics Inc. - F. Hoffmann-La Roche Ltd. - Fina Biotech - Generon (Shanghai) Corporation Ltd. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - GliaMed, Inc. - Green Cross Corporation - Huons Co., Ltd. - InVasc Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Jeil Pharmaceutical Co., Ltd. - Kolon Life Science, Inc. For more information visit http://www.researchandmarkets.com/research/4c...e_pipeline
Anavex Appoints Dr. Abraham Fisher to Scientific Advisory Board
GlobeNewswire - Wed May 28, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today the appointment of Abraham Fisher, PhD, to its Scientific Advisory Board (SAB). With nearly 40 years of experience in drug design and discovery, Dr. Fisher has taken lead compounds including AF102B (EVOXAC, cevimeline HCl) from concept to approval. AF102B was the first muscarinic agonist approved for sale in the U.S. (2000) and in Japan (2001) to treat dry mouth in patients with Sjoergen's Syndrome. He is also the inventor of AF710B (renamed ANAVEX 3-71), the unique and promising preclinical Alzheimer's drug candidate for which we recently obtained exclusive worldwide rights.
Anavex Reports That New Data Confirms Calcium Target Over-Expression May be Involved in Causing Alzheimer's Disease
GlobeNewswire - Thu May 22, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, welcomes new data published in the current issue of The Journal of Neuroscience that has favorable implications for ANAVEX PLUS, the Company's Alzheimer's disease drug candidate combination.
Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS.
Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
GlobeNewswire - Thu Mar 27, 12:00PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal ("IPI Journal" predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer's disease based on the Alzheimer's Disease Assessment Scale-Cognitive ("ADAS-Cog" , especially when combined with donepezil (Aricept(R)), the world's best-selling Alzheimer's drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer's while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014.
Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
GlobeNewswire - Wed Mar 19, 6:37AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014, the private placement of $10 million in principal amount of convertible debentures with several institutional and accredited investors, including U.S. and international healthcare funds. In addition, the investors received warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.
Anavex Life Sciences signs USD10m private placement to execute clinical trial Phase 1b/2a in Alzheimer's and advance product portfolio
M2 - Fri Mar 14, 4:01AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) said on Thursday that it has signed a private placement of USD10m of convertible debentures with several institutional and accredited investors, including US and international healthcare funds,.
Anavex Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Thu Mar 13, 9:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate.
Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models.
Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
GlobeNewswire - Tue Mar 04, 6:33AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014.
Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
GlobeNewswire - Wed Feb 26, 7:42AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel.
Anavex to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 1:00 p.m. ET in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel in New York, NY.
Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
GlobeNewswire - Thu Jan 23, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's.
Anavex Achieves Key Milestone as it Secures cGMP Manufacturing for Drug Candidate Trial Supplies
GlobeNewswire - Mon Jul 21, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that it has secured cGMP manufacturing of ANAVEX 2-73 for its drug candidate trial supplies. ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer's Hallmarks in Preclinical Disease Model
GlobeNewswire - Mon Jul 14, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical data for ANAVEX 3-71 (formerly AF710B) in a presentation at the 2014 Alzheimer's Association International Conference (AAIC). Anavex Announces Report Expanding Opportunity for Therapeutic Application of Anavex Compounds
GlobeNewswire - Mon Jun 30, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced that a paper in the current issue of the peer-reviewed scientific journal, Neurochemical Research, reveals for the first time that sigma-1 receptors (S1R) functionally downregulate certain proteins that play a major role in various pathophysiological conditions including depression, anxiety, epilepsy and brain injury following ischemic stroke. Acute Pain - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qlbxfm/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Nektar Therapeutics - Santen Pharmaceutical Co., Ltd. - Pacira Pharmaceuticals, Inc. - AcelRx Pharmaceuticals, Inc. - Laboratorios Del Dr. Esteve S.A. - Pfizer Inc. - Sigma-Tau S.p.A. - A. Menarini Industrie Farmaceutiche Riunite Srl - Anavex Life Sciences Corp. - Nuvo Research Inc. - Zalicus Inc. - Yungjin Pharm Ind. Co., Ltd. - Array BioPharma Inc. - Orexo AB - Insys Therapeutics, Inc. - Grunenthal GmbH - AngioChem Inc. - Charleston Laboratories, Inc. - Trevena, Inc. - Syntrix Biosystems, Inc. - Kineta, Inc. - QRxPharma Limited - Cara Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - Encore Therapeutics Inc. - Madeira Therapeutics For more information visit http://www.researchandmarkets.com/research/qlbxfm/acute_pain
Anavex wins new US patent for ANAVEX 3-71 for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance
M2 - Thu Jun 05, 3:25AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) disclosed on Wednesday the receipt of the US Patent Number 8,673,931 covering ANAVEX 3-71 (formerly AF710B) for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance.
Anavex Awarded New U.S. Patent
GlobeNewswire - Wed Jun 04, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931 (the "Patent" . The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer's disease (AD), type 2 diabetes and insulin resistance. ANAVEX obtained exclusive rights to worldwide patents and patent applications for ANAVEX 3-71 and related compounds in March 2014 from Life Science Research Israel, a subsidiary of the Israel Institute for Biological Research. The Patent has a term that expires no earlier than April 29, 2030. Anavex Life Sciences elects Dr Abraham Fisher to SAB
M2 - Thu May 29, 3:21AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) revealed on Wednesday the addition of Abraham Fisher PhD, to its scientific advisory board (SAB).
Stroke - Pipeline Review, H1 2014: Includes 62 Company Profiles
M2 - Thu May 29, 3:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4c67qc/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned Include: - AGY Therapeutics, Inc. - APT Therapeutics, Inc. - Acorda Therapeutics, Inc. - Ampio Pharmaceuticals, Inc. - Anavex Life Sciences Corp. - Angion Biomedica Corp. - ArmaGen Technologies, Inc. - Aronora, LLC - AstraZeneca PLC - CHA Bio & Diostech Co., Ltd. - CardioVascular BioTherapeutics, Inc. - CoDa Therapeutics, Inc. - Covigilance sro - D-Pharm Ltd. - Diakron Pharmaceuticals, Inc. - Dongwha Pharm Co., Ltd. - Encore Therapeutics Inc. - F. Hoffmann-La Roche Ltd. - Fina Biotech - Generon (Shanghai) Corporation Ltd. - Georgia Tech Research Corporation - GlaxoSmithKline plc - Glenmark Pharmaceuticals Ltd. - GliaMed, Inc. - Green Cross Corporation - Huons Co., Ltd. - InVasc Therapeutics, Inc. - Inbiopro Solutions Pvt. Ltd. - Jeil Pharmaceutical Co., Ltd. - Kolon Life Science, Inc. For more information visit http://www.researchandmarkets.com/research/4c...e_pipeline
Anavex Appoints Dr. Abraham Fisher to Scientific Advisory Board
GlobeNewswire - Wed May 28, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, announced today the appointment of Abraham Fisher, PhD, to its Scientific Advisory Board (SAB). With nearly 40 years of experience in drug design and discovery, Dr. Fisher has taken lead compounds including AF102B (EVOXAC, cevimeline HCl) from concept to approval. AF102B was the first muscarinic agonist approved for sale in the U.S. (2000) and in Japan (2001) to treat dry mouth in patients with Sjoergen's Syndrome. He is also the inventor of AF710B (renamed ANAVEX 3-71), the unique and promising preclinical Alzheimer's drug candidate for which we recently obtained exclusive worldwide rights. Anavex Reports That New Data Confirms Calcium Target Over-Expression May be Involved in Causing Alzheimer's Disease
GlobeNewswire - Thu May 22, 6:27AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's disease, other diseases of the central nervous system (CNS) and various types of cancer, welcomes new data published in the current issue of The Journal of Neuroscience that has favorable implications for ANAVEX PLUS, the Company's Alzheimer's disease drug candidate combination. Anavex Strengthens Alzheimer's Pipeline, Obtains Exclusive Worldwide Rights to Intellectual Property
GlobeNewswire - Mon Mar 31, 7:15AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has strengthened its Alzheimer's pipeline by obtaining exclusive rights to worldwide patents and patent applications covering methods and compositions for AF710B and other related, preclinical stage compounds from Life Science Research Israel Ltd. (LSRI). LSRI has a proven track record of successfully developing and bringing drugs to market. The licensing of AF710B complements Anavex's existing pipeline in Alzheimer's disease, which is the company's core competency and includes lead clinical candidate ANAVEX PLUS. Anavex Reports Predicted Clinical Effect of Both ANAVEX 2-73 and ANAVEX PLUS in a Humanized Cortical Cognitive Model for Alzheimer's Disease
GlobeNewswire - Thu Mar 27, 12:00PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced that a report in the current issue of peer-reviewed International Pharmaceutical Industry Journal ("IPI Journal" predicts that ANAVEX 2-73 will have a meaningful effect in Alzheimer's disease based on the Alzheimer's Disease Assessment Scale-Cognitive ("ADAS-Cog" , especially when combined with donepezil (Aricept(R)), the world's best-selling Alzheimer's drug. The Company believes this drug combination, called ANAVEX PLUS, is a compelling commercial opportunity because of its potential to treat symptoms of Alzheimer's while also possibly modifying or reversing the course of the disease. A Phase 1b/2a clinical trial of ANAVEX PLUS, is scheduled to begin mid 2014. Anavex Successfully Closes $10 Million Financing to Initiate Phase 1b/2a Alzheimer's Clinical Trial
GlobeNewswire - Wed Mar 19, 6:37AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has closed, as previously announced on March 13, 2014, the private placement of $10 million in principal amount of convertible debentures with several institutional and accredited investors, including U.S. and international healthcare funds. In addition, the investors received warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate. Anavex Life Sciences signs USD10m private placement to execute clinical trial Phase 1b/2a in Alzheimer's and advance product portfolio
M2 - Fri Mar 14, 4:01AM CDT
Biopharmaceutical company Anavex Life Sciences (Other OTC:AVXL) said on Thursday that it has signed a private placement of USD10m of convertible debentures with several institutional and accredited investors, including US and international healthcare funds,.
Anavex Announces $10 Million Private Placement of Convertible Debentures
GlobeNewswire - Thu Mar 13, 9:36AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, announced today that it has entered into definitive agreements with several institutional and accredited investors, including U.S. and international healthcare funds, for a private placement of approximately $10 million in principal amount of convertible debentures. In addition, the investors will receive warrants to purchase up to approximately 66.7 million shares of common stock in the aggregate. Anavex Encouraged By Scientific Data Confirming Sigma-1 Receptor Agonist Extends Survival in ALS (Lou Gehrig's Disease)
GlobeNewswire - Mon Mar 10, 6:39AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer's, diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research report published in the current issue of peer-reviewed scientific journal Neuroscience Letters. The Company is encouraged by the report because its results point to potential for ANAVEX 2-73 to treat ALS, also known as Lou Gehrig's disease. Data showed that sigma-1 receptor (S1R) agonists are effective in suppressing motor neuron degeneration and symptom progression in ALS animal models. Anavex: Research Report Reveals Cardioprotective Action of Sigma-1 Receptor Agonists
GlobeNewswire - Tue Mar 04, 6:33AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) is encouraged by the findings of a research report published in the current issue of peer-reviewed scientific journal Life Sciences. Among its conclusions, the report reveals that sigma-1 receptor (S1R) agonists play an important role in the prevention, delay or reduction of heart disease. These findings correlate with the positive electrocardiogram (EKG) parameters in the successfully completed human clinical Phase 1 safety trial of ANAVEX 2-73, an orally available S1R agonist drug candidate developed to treat Alzheimer's through potential disease modification. ANAVEX 2-73 has also shown highly encouraging synergy with donepezil, the world's best-selling Alzheimer's drug, and a Phase 1b/2a clinical trial of this combination, ANAVEX PLUS, is planned for the first half of 2014. Research Report Confirms Opportunity for Anavex Anti-Cancer and Neuropathic Pain Compounds
GlobeNewswire - Wed Feb 26, 7:42AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) today announced that a research article in the current issue of peer-reviewed scientific journal Molecular Pain reveals a new opportunity for the Company's anti-cancer and neuropathic pain compounds. The article describes that sigma-1 receptor (S1R) modulation prevents neuropathic pain and mitochondrial abnormalities induced by the chemotherapy drug paclitaxel. Anavex to Present at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 03, 6:27AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will be presenting at the 16th Annual BIO CEO & Investor Conference on Monday, February 10, 2014, at 1:00 p.m. ET in the Conrad Room. The conference will be held at the Waldorf-Astoria Hotel in New York, NY. Sigma-1 receptor Implicated in Cell Survival of Rare Neurodegenerative Diseases - Expanding the Opportunity for Application of ANAVEX PLUS in Rare Diseases
GlobeNewswire - Thu Jan 23, 6:17AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(OTCQB:AVXL) today announced that a publication in the current issue of scientific journal Neuropathology potentially extends the opportunity for ANAVEX PLUS to additional neurodegenerative diseases beyond Alzheimer's. 
